<p>Innovent Biologics Inc. said China’s National Medical Products Administration has approved Jaypirca (pirtobrutinib), a non-covalent BTK inhibitor, for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least one prior systemic therapy including a BTK inhibitor. The company said the approval was supported by results from the Phase 3 BRUIN CLL-321 trial comparing pirtobrutinib with investigator’s choice regimens. Innovent said pirtobrutinib is developed by Eli Lilly and Company and commercialized in mainland China by Innovent. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260227-12032576), on February 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

589720

513060

588250

<p>Innovent Biologics Inc. announced that China's National Medical Products Administration has approved Jaypirca (pirtobrutinib) for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, following at least one prior systemic therapy. The approval is based on the Phase 3 BRUIN CLL-321 trial results. Pirtobrutinib is developed by Eli Lilly and is commercialized in mainland China by Innovent.</p>

PUBT

Guotai SSE STAR Brand Name Drug ETF

Bosera Hang Seng Health Care ETF(QDII)

Penghua SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

Penghua CSI HK Connect Health Care Composite ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

INNOVENT BIO

ChinaAMC SSE Health Care ETF Initiating Fund

China Universal CNI HK Connect Innovative Drugs Industry ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Ping An CSI Medicine and Medical Device Innovation ETF

China Southern Hang Seng Biotech ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Tianhong CNI BIOMEDICINE ETF

Innovent Says China NMPA Approves Jaypirca for Relapsed or Refractory CLL/SLL